# NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

> **NCT06966583** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 20 (estimated)

## Conditions studied

- Solid Tumor
- Non Small Cell Lung Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** NAD supplement
- **RADIATION:** Radiotherapy
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT06966583
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06966583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06966583, "NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06966583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*